Study of Losartan in the Treatment of NAFLD in Children

Phase 2

Completed

Conditions: NAFLD

Interventions: Drug: Losartan

Registration Number: NCT01913470

Lead Sponsor: Miriam Vos, MD

Brief Summary: Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease among children and is closely associated with obesity and the metabolic syndrome. NAFLD increases risk of mortality and natural history studies of adults show that NAFLD is an independent risk factor for cardiovascular disease. Pediatric NAFLD is particularly concerning from a public health standpoint, as it represents an early and possibly more aggressive form of the disease. Currently there is no effective treatment for pediatric NAFLD.

Losartan is an orally-administered angiotensin II receptor antagonist which is currently on the market to treat high blood pressure. The renin-angiotensin-aldosterone (RAA) system has been shown to be important in many disease states including renal disease, cardiovascular disease, and NAFLD. Angiotensin antagonists are a class of medications that has been proposed as a novel treatment of NAFLD in part because they would treat both the factors increasing cardiovascular (CVD) risks as well as potentially improve steatosis, fibrosis and hepatic inflammation.

This study is a randomized, double-blinded, placebo-controlled pilot study to evaluate whether 8 weeks of Losartan will decrease inflammatory markers among children ages 12-19 with a current diagnosis of NAFLD. Efficacy will be assessed by improvement in alanine aminotransferase (ALT) from baseline. Secondary endpoints will include aspartate aminotransferase (AST), cytokeratin 18 levels, and fasting triglyceride levels among others. Safety will be assessed by the recording of adverse events, clinical laboratory parameters, vital signs and physical examinations.

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 12

Inclusion Criteria

Body Mass Index (BMI) > 85th% for age and gender
History of definite or borderline nonalcoholic steatohepatitis (NASH) diagnosed by liver biopsy using NASH Clinical Research Network (CRN) criteria
At least 2 months of attempted lifestyle changes after liver biopsy
Current ALT ≥ 3 times normal (69 U/L for girls, 78 U/L for boys) at enrollment
Glomerular filtration rate (GRF) > 90
Weight ≥ 62.5 kg

Exclusion Criteria

Other chronic illness requiring daily medication (except medications for mild mental illness, acid reflux, allergies, stable attention deficit hyperactivity disorder (ADHD), or asthma)
Supplement or anti-oxidant therapy within past 2 weeks
Renal insufficiency
Cirrhosis and liver synthetic dysfunction (International Normalized Ratio ≥ 1.5)
History of hypotension
Diabetes (or fasting glucose > 125 mg/dL)
Acute illness within past 2 weeks prior to enrollment (fever > 100.4ºF)
Pregnancy

Study & Design

Study Type: INTERVENTIONAL

Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Losartan then Placebo	Losartan	0.4mg/kg/day (max 25mg) for one week and then increase to 0.8mg/kg/day (max 50mg) for 7 additional weeks then placebo pill for 8 weeks
Sugar pill	Losartan	placebo pill taken for 8 weeks then 0.4mg/kg/day (max 25mg) for one week and then increase to 0.8mg/kg/day (max 50mg) for 7 additional weeks

Primary Outcome Measures

Name	Time	Method
Change in Alanine Aminotransferase (ALT) From Baseline to End of Treatment (8 Weeks of Treatment)	Baseline (Weeks 0 and 14), Endpoint (Weeks 8 and 22)	The principal objective of this blinded, placebo controlled, crossover pilot study is to evaluate whether 8 weeks of losartan in children with nonalcoholic steatohepatitis (NASH) will decrease inflammation as measured by ALT.

Secondary Outcome Measures

Name	Time	Method
Change in Triglyceride Levels From Baseline to End of Treatment (8 Weeks of Treatment)	Baseline (Week 0 and 14), End of treatment (Week 8 and 22)	For children aged 10 to 19, triglyceride levels of less than 90 is considered acceptable, 90 to 129 is borderline high, and greater than or equal to 130 and over is high.
Changes in Homeostasis Model of Assessment - Insulin Resistance (HOMA-IR) Between Baseline and End of Treatment (8 Weeks of Treatment)	Baseline (Week 0 and 14), End of Treatment (Week 8 and 22)	Homeostasis Model of Assessment - Insulin Resistance (HOMA-IR) is an equation which indicates the degree of insulin resistance, where higher scores equate to greater insulin resistance. HOMA-IR is calculated as fasting glucose (mg/dl) × insulin (mU/L)/405. A HOMA-IR value \>2.0 in prepubertal children and \>2.6 in pubertal children, may be considered a warning sign for pediatricians to further investigate insulin resistance.
Change in Cholesterol Levels From Baseline to End of Treatment (8 Weeks of Treatment)	Baseline (Week 0 and 14), End of treatment (Week 8 and 22)	For children, a cholesterol level of less than 170 is considered acceptable, 170-199 is borderline high, and 200 and over is high.
Changes in Plasminogen Activator Inhibitor-1 (PAI-1) Concentrations Between Baseline and End of Treatment	Baseline, Week 8, Week 14, Week 22	PAI-1 is an acute-phase protein that is associated with both injury and inflammation, and has been found to be elevated in adolescents with significant hepatic steatosis. The reference range for PAI-1 in fasting adults is 3-72 ng/mL
Change in Fatty Acid Levels From Baseline to End of Treatment (8 Weeks of Treatment)	Baseline (Week 0 and 14), End of Treatment (Week 8 and 22)	In human studies, losartan has been shown to decrease serum free fatty acids, thus any decrease in this measurement indicates a positive response to losartan.